1. Cybin's Intellectual Property : Cybin has over 70 granted patents and 220 patent applications pending across multiple patent families.Read more
Cybin is trying to make psychedelic treatments fit into everyday mental health clinics by designing sessions that use less staff time and by teaming up with partners that already support drug manufacturing and clinic workflows. The big question is whether upcoming study results and real-world clinic and insurance adoption arrive fast enough to justify today’s expectations.Read more
Cybin is trying to bring psychedelic-style treatments for depression and anxiety into clinics in a way that fits today’s mental-health workflows, which could speed up real-world use if the late-stage trials deliver. The big question is whether the studies succeed and whether insurers and clinics adopt the model fast enough to turn scientific progress into a sustainable business.Read more
Cybin is racing to bring psychedelic-based treatments for depression and anxiety through late-stage trials, but it may need to raise more money before it ever sells a product. If the studies run smoothly and clinics and insurers embrace short, streamlined treatment sessions, the payoff could be meaningful—but a delay, weaker results, or slow adoption could quickly change the story.Read more
No trending discussion available.
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’ preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
